As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

Reflecting this potential, Goldman Sachs analyst Asad Haider on August 15 reiterated a Buy rating on Eli Lilly and Company ...

Eli Lilly's Orforglipron helped patients with obesity and Type 2 diabetes lose over 10% body weight in phase 3 trials, ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...

Virginia lawmakers have approved two proposed economic development packages for advanced pharmaceutical manufacturing plants ...

As of Tuesday's close, Lilly's stock is down 4.6% in 2025, while the S&P 500 SPX has risen 9.5% and the iShares U.S. Pharmaceuticals exchange-traded fund IHE has risen 6.6%.

For Tuesday, Aug. 26, WGN’s Ben Bradley and Lourdes Duarte have the latest on new medical information, including: Eli Lilly ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Virginia lawmakers have approved two proposed economic development packages for advanced pharmaceutical manufacturing plants ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The S&P 500 added 0.4% on Tuesday, Aug. 26, 2025, as investors looked past concerns about President Trump's move to fire a ...